Drug treatments in Alzheimer’s disease
Robert Briggs, Sean P Kennelly and Desmond O'Neill
DOI: https://doi.org/10.7861/clinmedicine.16-3-247
Clin Med June 2016 Robert Briggs
ACentre for Ageing, Neuroscience and the Humanities, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland
Roles: research fellow
Sean P Kennelly
BCentre for Ageing, Neuroscience and the Humanities, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland
Roles: consultant geriatrician and stroke physician
Desmond O'Neill
CCentre for Ageing, Neuroscience and the Humanities, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland
Roles: consultant geriatrician and professor of medical gerontology
Article Information
vol. 16 no. 3 247-253
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Published online June 1, 2016.
Copyright & Usage:
© 2016 Royal College of Physicians
Author Information
- Robert Briggs, research fellowA,
- Sean P Kennelly, consultant geriatrician and stroke physicianB and
- Desmond O'Neill, consultant geriatrician and professor of medical gerontologyC
- ACentre for Ageing, Neuroscience and the Humanities, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland
- BCentre for Ageing, Neuroscience and the Humanities, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland
- CCentre for Ageing, Neuroscience and the Humanities, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland
- Address for correspondence: Dr R Briggs, Centre for Aging, Neuroscience and the Humanities, Trinity Centre for Health Sciences, Tallaght Hospital, Dublin, Ireland. Email: briggsr{at}tcd.ie
Article usage
Article Tools
Drug treatments in Alzheimer’s disease
Robert Briggs, Sean P Kennelly, Desmond O'Neill
Clinical Medicine Jun 2016, 16 (3) 247-253; DOI: 10.7861/clinmedicine.16-3-247
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- Characterizing Treatment Non-responders vs. Responders in Completed Alzheimers Disease Clinical Trials
- Repetitive Transcranial Magnetic Stimulation as a Treatment for Veterans with Cognitive Impairment and Multiple Comorbidities
- Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimers disease therapy
- Decreased Levels of Blood AMPK{alpha}1 but not AMPK{alpha}2 Isoform in Patients with Mild Cognitive Impairment and Alzheimers Disease: A Pilot Study
- Modulation of Amyloid States by Molecular Chaperones